Regulating autologous adult stem cells: the FDA steps up.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22056136.
- Also identified by DOI 10.1016/j.stem.2011.09.013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Food and Drug Administration (FDA) has sought an injunction to prevent a US-based company from offering an autologous adult stem cell treatment for musculoskeletal and spinal injuries. Given the alarming number of clinics promoting stem-cell-based interventions, the outcome of this case could have wide-ranging implications.
Medical subject headings
- Adult Stem Cells
- United States Food and Drug Administration